WASHINGTON, D.C.—CMS has issued a final rule eliminating Part D plans’ and PBMs’ use of retroactive direct and indirect remuneration (DIR) fees beginning on January 1, 2024 (contract year 2024). The American Pharmacists Association (APhA) and many of its members submitted comments to CMS on the proposal. APhA appreciates CMS’ efforts to end the uncertainty and lack of drug cost transparency at the pharmacy caused by retroactive DIR fees.

WASHINGTON, DC – The American Pharmacists Association released the following statement in response to an April 12, 2022, letter from the American Medical Association (AMA) to Representatives Kind and McKinley regarding H.R. 7213, the “Equitable Community Access to Pharmacist Services Act.”  

WASHINGTON, D.C.—The American Pharmacists Association (APhA) is committed to facilitating meaningful dialogue between pharmacy management, pharmacy team members, and other stakeholders that results in improved workplaces, well-being, and the ability to meet ethical obligations to patient safety. 

WASHINGTON, DC and BESSEMER, AL—Plan sponsors and PBMs who manage prescription drug benefits under Medicare Part D are shifting costs and risks to America’s seniors and taxpayers by artificially inflating prescription drug costs at the pharmacy counter, according to a groundbreaking new study released today.